Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706. doi: 10.1007/s00280-008-0725-7. Epub 2008 Mar 13.

Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy.

Author information

  • 1Departments of Pediatrics, Neurology & Neurobiology and Anatomy, University of Rochester Medical Center, Rochester, NY, USA.

Abstract

PURPOSE:

To identify and mathematically model molecular predictors of response to the enediyne chemotherapeutic agent, neocarzinostatin, in nervous system cancer cell lines.

METHODS:

Human neuroblastoma, breast cancer, glioma, and medulloblastoma cell lines were maintained in culture. Content of caspase-3 and Bcl-2, respectively, was determined relative to actin content for each cell line by Western blotting and optical densitometry. For each cell line, sensitivity to neocarzinostatin was determined. Brain tumor cell lines were stably transfected with human Bcl-2 cDNA cloned into the pcDNA3 plasmid vector.

RESULTS:

In human tumor cell lines of different tissue origins, sensitivity to neocarzinostatin is proportional to the product of the relative contents of Bcl-2 and caspase-3 (r (2) = 0.9; P < 0.01). Neuroblastoma and brain tumor cell lines are particularly sensitive to neocarzinostatin; the sensitivity of brain tumor lines to neocarzinostatin is enhanced by transfection with an expression construct for Bcl-2 and is proportional in transfected cells to the product of the relative contents of Bcl-2 and caspase-3 (r (2) = 0.7).

CONCLUSION:

These studies underscore the potential of molecular profiling in identifying effective chemotherapeutic paradigms for cancer in general and tumors of the nervous system in particular.

PMID:
18338171
[PubMed - indexed for MEDLINE]
PMCID:
PMC2575071
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk